Publications by authors named "Kyle Baron"

Claim this Profile
E
Exposure-Response Relationships in Patients with Non-Small-Cell Lung Cancer and Other Solid Tumors Treated with Patritumab Deruxtecan (HER3-DXd).
Li Li, Mark Lee, Rujuta Joshi, Yuan Xu, Ramon Garcia, Kyle Baron

Clin Pharmacol Ther· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics of total and unbound valemetostat and platelet dynamics in healthy volunteers and patients with non-Hodgkin lymphoma.
Masato Fukae, Kyle Baron, Masaya Tachibana, John Mondick, Takako Shimizu

CPT Pharmacometrics Syst Pharmacol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetic modeling of vedolizumab for graft-versus-host disease prophylaxis in adults with allogeneic hematopoietic stem cell transplant.
Timothy Waterhouse, Kyle Baron, Westley Eure, Chunlin Chen, Nathanael L Dirks

Pharmacol Res Perspect· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
gPKPDviz: A flexible R shiny tool for pharmacokinetic/pharmacodynamic simulations using mrgsolve.
Tong Lu, Victor Poon, Logan Brooks, Erick Velasquez, Eric Anderson, Kyle Baron

CPT Pharmacometrics Syst Pharmacol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A model-based analysis to guide gonadotropin-releasing hormone receptor antagonist use for management of endometriosis.
Oliver Pohl, Kyle Baron, Matthew Riggs, Jonathan French, Ramon Garcia

Br J Clin Pharmacol· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantitative Systems Pharmacology and Physiologically-Based Pharmacokinetic Modeling With mrgsolve: A Hands-On Tutorial.
Ahmed Elmokadem, Matthew M Riggs, Kyle T Baron

CPT Pharmacometrics Syst Pharmacol· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population Pharmacokinetics and Exposure-Response (Efficacy and Safety/Tolerability) of Empagliflozin in Patients with Type 2 Diabetes.
Kyle T Baron, Sreeraj Macha, Uli C Broedl, Valerie Nock, Silke Retlich

Diabetes Ther· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bayesian approach to estimate AUC, partition coefficient and drug targeting index for studies with serial sacrifice design.
Tianli Wang, Kyle Baron, Wei Zhong, Richard Brundage, William Elmquist

Pharm Res· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NMDA-evoked consumption and recovery of mitochondrially targeted aequorin suggests increased Ca2+ uptake by a subset of mitochondria in hippocampal neurons.
Kyle T Baron, Guang Jian Wang, Rodolfo A Padua, Colin Campbell, Stanley A Thayer

Brain Res· December 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis